After 722, 40 products got NDA application; We are number one in the industry, which proved that our quality is consistent.
We are responsible for the development of hepatitis drugs in China, and the most popular PD-1/PD-L1 immune tumor experiment to undertake 50+.
Through high quality service, we have won unanimous praise from the sponsors, investgators and CRO partners, and the repeat business rate is up to 90%.
Audit by top 10 global pharmaceutical companies and 5 global CROs
100+ studies were inspected by NMPA
2 projects were inspected by EMA♤5 project was inspected by FDA